Dinko Vitezić (Dinko Vitezic)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 12

Top Topics

Randomized Controlled Trial

Health Insurance

Mesenchymal Stem Cells

Top Venues

Journal of clinical medicine

Journal of personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Andrej Belančić, Tea Strbad, Marta Kučan Štiglić, Dinko Vitezić
Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Journal of personalized medicine 14 (3) (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy 31 (7-8) (2024)
Andrej Belančić, Tea Strbad, Marta Kučan Štiglić, Dinko Vitezić
Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Journal of personalized medicine 14 (3) (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy 31 (7-8) (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy 31 (7-8) (2024)
Andrej Belančić, Tea Strbad, Marta Kučan Štiglić, Dinko Vitezić
Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data. Journal of clinical medicine 12 (8) (2023)
Andrej Belančić, Tea Strbad, Marta Kučan Štiglić, Dinko Vitezić
Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data. Journal of clinical medicine 12 (8) (2023)
Andrej Belančić, Tea Strbad, Marta Kučan Štiglić, Dinko Vitezić
Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data. Journal of clinical medicine 12 (8) (2023)
Andrej Belančić, Tea Strbad, Marta Kučan Štiglić, Dinko Vitezić
Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data. Journal of clinical medicine 12 (8) (2023)